用于靶向α治疗的230U生产反应232Th(p,3n)230Pa的截面。
Cross-sections of the reaction 232Th(p,3n)230Pa for production of 230U for targeted alpha therapy.
作者信息
Morgenstern Alfred, Apostolidis Christos, Bruchertseifer Frank, Capote Roberto, Gouder Thomas, Simonelli Federica, Sin Mihaela, Abbas Kamel
机构信息
European Commission, Joint Research Centre, Institute for Transuranium Elements, P.O. Box 2340, 76125 Karlsruhe, Germany.
出版信息
Appl Radiat Isot. 2008 Oct;66(10):1275-80. doi: 10.1016/j.apradiso.2008.02.066. Epub 2008 Feb 20.
(230)U/(226)Th is a promising novel alpha-emitter system for application in targeted alpha therapy of cancer. The therapeutic nuclides can be produced by proton irradiation of natural (232)Th according to the reaction (232)Th(p,3n)(230)Pa, followed by subsequent beta decay of (230)Pa to (230)U. In this study, the experimental excitation function for the (232)Th(p,3n)(230)Pa reaction up to 34 MeV proton energy has been measured using the stacked-foil technique. The proton energies in the various foils were calculated with the SRIM 2003 code and gamma-ray spectrometry was used to measure the activities of the various radioisotopes produced. The measured cross-sections are in good agreement with selected literature values and with model calculations using the EMPIRE II code. The reaction (232)Th(p,3n)(230)Pa allows the production of carrier-free (230)U in clinically relevant levels.
（230）U/（226）Th是一种很有前景的新型α发射体系统，可应用于癌症的靶向α治疗。治疗性核素可通过质子辐照天然（232）Th，按照反应（232）Th（p，3n）（230）Pa制备，随后（230）Pa发生β衰变生成（230）U。在本研究中，使用叠层箔技术测量了质子能量高达34 MeV时（232）Th（p，3n）（230）Pa反应的实验激发函数。利用SRIM 2003程序计算了各箔片中的质子能量，并使用γ射线光谱法测量了所产生的各种放射性同位素的活度。测得的截面与选定的文献值以及使用EMPIRE II程序的模型计算结果吻合良好。反应（232）Th（p，3n）（230）Pa能够产生临床相关水平的无载体（230）U。
Zotero 插件